{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:52:22Z","timestamp":1794243142916,"version":"4.9.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1136\/ijgc-2023-004980","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:45:16Z","timestamp":1705452316000},"page":"88-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival?"],"prefix":"10.1016","volume":"34","author":[{"given":"Carolina Maria","family":"Sassu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-8956","authenticated-orcid":false,"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0833-4334","authenticated-orcid":false,"given":"Angelo","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-1263","authenticated-orcid":false,"given":"Serena Maria","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Benato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7164-4952","authenticated-orcid":false,"given":"Alessia","family":"Piermattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Mattogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Olivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-1063","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004980_bb0010","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/IGC.0000000000000007","article-title":"Ovarian cancer: sites of recurrence","volume":"23","author":"Amate","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004980_bb0015","first-page":"2793","article-title":"Brain metastases from epithelial ovarian cancer: overview and optimal management","volume":"29","author":"Pietzner","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2023-004980_bb0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/B:NEON.0000014516.04943.38","article-title":"Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome","volume":"66","author":"Cohen","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1136\/ijgc-2023-004980_bb0025","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1634\/theoncologist.11-3-252","article-title":"Brain metastases from epithelial ovarian cancer: a review of the literature","volume":"11","author":"Pectasides","year":"2006","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2023-004980_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.847110","article-title":"Surgical management of brain metastasis: challenges and nuances","volume":"12","author":"Ene","year":"2022","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0035","doi-asserted-by":"crossref","DOI":"10.3171\/2023.5.FOCUS23115","article-title":"Surgical management of brain metastasis from ovarian cancer: a systematic review and case series","volume":"55","author":"Costello","year":"2023","journal-title":"Neurosurg Focus"},{"key":"10.1136\/ijgc-2023-004980_bb0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ygyno.2019.05.004","article-title":"Brain metastasis in epithelial ovarian cancer by BRCA1\/2 mutation status","volume":"154","author":"Stasenko","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23788-4","article-title":"Pathway-level mutation analysis in primary high-grade serous ovarian cancer and matched brain metastases","volume":"12","author":"Duchnowska","year":"2022","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2023-004980_bb0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-017-2459-z","article-title":"Next-generation sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations","volume":"133","author":"Balendran","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1136\/ijgc-2023-004980_bb0055","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004980_bb0060","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-Ov16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0065","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 Mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0070","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/0284186X.2022.2066985","article-title":"Brain metastases in patients with ovarian cancer","volume":"61","author":"Limon","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0075","article-title":"Successful treatment of a patient with brain metastasis from ovarian cancer with BRCA wild type using niraparib: a case report and review of the literature","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"Suppl 4","key":"10.1136\/ijgc-2023-004980_bb0080","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.4103\/2152-7806.111298","article-title":"Imaging of brain metastases","volume":"4","author":"Fink","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1136\/ijgc-2023-004980_bb0085","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN guidelines\u00ae insights: ovarian cancer, version 3.2022","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2023-004980_bb0090","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2019.03.004","article-title":"Increased risk of brain metastases in ovarian cancer patients with BRCA mutations","volume":"153","author":"Ratner","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-014-1447-9","article-title":"Brain metastasis from ovarian cancer: a systematic review","volume":"119","author":"Pakneshan","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1136\/ijgc-2023-004980_bb0105","first-page":"527453","article-title":"Brain metastases from ovarian carcinoma","volume":"2011","author":"Piura","year":"2011","journal-title":"ISRN Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0110","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2023-004980_bb0115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2023-004980_bb0125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004980_bb0130","first-page":"A25","author":"Sassu","year":"2023"},{"issue":"13_Supplement","key":"10.1136\/ijgc-2023-004980_bb0135","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1538-7445.AM2019-3888","article-title":"Abstract 3888: intracranial evaluation of the in vivo pharmacokinetics, brain distribution, and efficacy of Rucaparib in BRCA -mutant, triple-negative breast cancer","volume":"79","author":"Nguyen","year":"2019","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2023-004980_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230738","article-title":"Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases","volume":"12","author":"Gray","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1136\/ijgc-2023-004980_bb0145","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jog.13851","article-title":"Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: a case report","volume":"45","author":"Sakamoto","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1136\/ijgc-2023-004980_bb0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ijgc-2020-001849","article-title":"Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases","volume":"31","author":"Kasherman","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004980_bb0155","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.925990","article-title":"Clinically relevant response to treatment with olaparib in a patient with refractory multidrug-resistant ovarian cancer and central nervous system involvement: a case report","volume":"21","author":"Morales V\u00e1zquez","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1136\/ijgc-2023-004980_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.3110","article-title":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OREO\/ENGOT-Ov38): a phase IIIB trial","author":"Pujade-Lauraine","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004980_bb0165","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/1078-0432.CCR-22-3282","article-title":"Multi-maintenance olaparib therapy in relapsed, germline BRCA1\/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial","volume":"29","author":"Morgan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004980_bb0170","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2016.09.025","article-title":"Brain metastases in patients with EOC: clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group","volume":"143","author":"Marchetti","year":"2016","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:19:24Z","timestamp":1753229964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24013185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1048891X24013185"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004980","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/ijgc-2023-004980.supp1","asserted-by":"subject"}]},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}